MARCH 30, 2011 -- The March of Dimes welcomes today’s FDA statement, which lays to rest any ambiguities about whether specialty pharmacies can continue to compound 17-P. It would be a tragedy to interrupt access to this important drug.
To date, Ther-Rx Corporation’s handling of the launch of Makena has been unsatisfactory to the March of Dimes and to the families we represent. We’ve asked Ther-Rx in writing and in discussion to substantially lower the price of Makena and to expand coverage for patient financial assistance. We’re waiting for their public statement on this matter, which we expect will occur within the next week.
The March of Dimes number one concern is the health of mothers and babies. We will continue to work in a variety of ways to ensure that all medically eligible women have access to progesterone therapy.